- Home
- DEVS vs CGTX Comparison
DEVS vs CGTX Comparison
Compare DEVS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- CGTX
- Stock Information
- Founded
- DEVS N/A
- CGTX 2007
- Country
- DEVS Canada
- CGTX United States
- Employees
- DEVS N/A
- CGTX N/A
- Industry
- DEVS
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- CGTX Health Care
- Exchange
- DEVS NYSE
- CGTX Nasdaq
- Market Cap
- DEVS 16.5M
- CGTX 16.1M
- IPO Year
- DEVS N/A
- CGTX 2021
- Fundamental
- Price
- DEVS $0.78
- CGTX $0.63
- Analyst Decision
- DEVS
- CGTX Strong Buy
- Analyst Count
- DEVS 0
- CGTX 6
- Target Price
- DEVS N/A
- CGTX $8.30
- AVG Volume (30 Days)
- DEVS 9.6M
- CGTX 20.0M
- Earning Date
- DEVS 02-12-2025
- CGTX 11-13-2024
- Dividend Yield
- DEVS N/A
- CGTX N/A
- EPS Growth
- DEVS N/A
- CGTX N/A
- EPS
- DEVS N/A
- CGTX N/A
- Revenue
- DEVS N/A
- CGTX N/A
- Revenue This Year
- DEVS N/A
- CGTX N/A
- Revenue Next Year
- DEVS N/A
- CGTX N/A
- P/E Ratio
- DEVS N/A
- CGTX N/A
- Revenue Growth
- DEVS N/A
- CGTX N/A
- 52 Week Low
- DEVS $0.48
- CGTX $0.34
- 52 Week High
- DEVS $1.91
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- CGTX 69.18
- Support Level
- DEVS N/A
- CGTX $0.43
- Resistance Level
- DEVS N/A
- CGTX $1.29
- Average True Range (ATR)
- DEVS 0.00
- CGTX 0.10
- MACD
- DEVS 0.00
- CGTX 0.03
- Stochastic Oscillator
- DEVS 0.00
- CGTX 27.88
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.